Regulatory T cells in solid organ transplantation
Abstract The induction of graft tolerance remains the holy grail of transplantation. This is important as chronic allograft dysfunction and the side effects of immunosuppression regimens place a major burden on the lives of transplant patients and their healthcare systems. This has mandated the need...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Clinical & Translational Immunology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cti2.1099 |
| _version_ | 1819226175195578368 |
|---|---|
| author | Muhammad Atif Filomena Conti Guy Gorochov Ye Htun Oo Makoto Miyara |
| author_facet | Muhammad Atif Filomena Conti Guy Gorochov Ye Htun Oo Makoto Miyara |
| author_sort | Muhammad Atif |
| collection | DOAJ |
| description | Abstract The induction of graft tolerance remains the holy grail of transplantation. This is important as chronic allograft dysfunction and the side effects of immunosuppression regimens place a major burden on the lives of transplant patients and their healthcare systems. This has mandated the need to understand the immunobiology of graft rejection and identify novel therapeutics. Regulatory T (Treg) cells play an important role in modulating pro‐inflammatory microenvironments and maintaining tissue homeostasis. However, there are fundamental unanswered questions regarding Treg cell immunobiology. These cells are a heterogeneous entity with functionally diverse roles. Moreover, the adoption of novel deeper immunophenotyping and genomic sequencing technologies has identified this phenotype and function to be more complex than expected. Hence, a comprehensive understanding of Treg cell heterogeneity is needed to safely and effectively exploit their therapeutic potential. From a clinical perspective, the recent decade has seen different clinical teams commence and complete first‐in‐man clinical trials utilising Treg cells as an adoptive cellular therapy. In this review, we discuss these trials from a translational perspective with an important focus on safety. Finally, we identify crucial knowledge gaps for future study. |
| first_indexed | 2024-12-23T10:21:18Z |
| format | Article |
| id | doaj.art-d7d91392e0904a768815a94d783fd06f |
| institution | Directory Open Access Journal |
| issn | 2050-0068 |
| language | English |
| last_indexed | 2024-12-23T10:21:18Z |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical & Translational Immunology |
| spelling | doaj.art-d7d91392e0904a768815a94d783fd06f2022-12-21T17:50:41ZengWileyClinical & Translational Immunology2050-00682020-01-0192n/an/a10.1002/cti2.1099Regulatory T cells in solid organ transplantationMuhammad Atif0Filomena Conti1Guy Gorochov2Ye Htun Oo3Makoto Miyara4Sorbonne Université Inserm U1135 Centre d'Immunologie et des Maladies Infectieuses (CIMI‐Paris) Hôpital Pitié‐Salpêtrière AP‐HP Paris FranceUnité de Transplantation Hépatique Hôpital Pitié‐Salpêtrière AP‐HP Paris FranceSorbonne Université Inserm U1135 Centre d'Immunologie et des Maladies Infectieuses (CIMI‐Paris) Hôpital Pitié‐Salpêtrière AP‐HP Paris FranceCentre for Liver and Gastro Research NIHR Birmingham Biomedical Research Centre University of Birmingham Birmingham UKSorbonne Université Inserm U1135 Centre d'Immunologie et des Maladies Infectieuses (CIMI‐Paris) Hôpital Pitié‐Salpêtrière AP‐HP Paris FranceAbstract The induction of graft tolerance remains the holy grail of transplantation. This is important as chronic allograft dysfunction and the side effects of immunosuppression regimens place a major burden on the lives of transplant patients and their healthcare systems. This has mandated the need to understand the immunobiology of graft rejection and identify novel therapeutics. Regulatory T (Treg) cells play an important role in modulating pro‐inflammatory microenvironments and maintaining tissue homeostasis. However, there are fundamental unanswered questions regarding Treg cell immunobiology. These cells are a heterogeneous entity with functionally diverse roles. Moreover, the adoption of novel deeper immunophenotyping and genomic sequencing technologies has identified this phenotype and function to be more complex than expected. Hence, a comprehensive understanding of Treg cell heterogeneity is needed to safely and effectively exploit their therapeutic potential. From a clinical perspective, the recent decade has seen different clinical teams commence and complete first‐in‐man clinical trials utilising Treg cells as an adoptive cellular therapy. In this review, we discuss these trials from a translational perspective with an important focus on safety. Finally, we identify crucial knowledge gaps for future study.https://doi.org/10.1002/cti2.1099clinical trialFOXP3regulatory T cellssafetytransplantTreg |
| spellingShingle | Muhammad Atif Filomena Conti Guy Gorochov Ye Htun Oo Makoto Miyara Regulatory T cells in solid organ transplantation Clinical & Translational Immunology clinical trial FOXP3 regulatory T cells safety transplant Treg |
| title | Regulatory T cells in solid organ transplantation |
| title_full | Regulatory T cells in solid organ transplantation |
| title_fullStr | Regulatory T cells in solid organ transplantation |
| title_full_unstemmed | Regulatory T cells in solid organ transplantation |
| title_short | Regulatory T cells in solid organ transplantation |
| title_sort | regulatory t cells in solid organ transplantation |
| topic | clinical trial FOXP3 regulatory T cells safety transplant Treg |
| url | https://doi.org/10.1002/cti2.1099 |
| work_keys_str_mv | AT muhammadatif regulatorytcellsinsolidorgantransplantation AT filomenaconti regulatorytcellsinsolidorgantransplantation AT guygorochov regulatorytcellsinsolidorgantransplantation AT yehtunoo regulatorytcellsinsolidorgantransplantation AT makotomiyara regulatorytcellsinsolidorgantransplantation |